<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01983735</url>
  </required_header>
  <id_info>
    <org_study_id>130HT13015</org_study_id>
    <nct_id>NCT01983735</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of TELMINUVO to Stage 2 Hypertension</brief_title>
  <official_title>A Randomized, Double-blind, Multi-center, Phase 3 Trial to Evaluate the Efficacy and Safety of a Fixed Dose Combination of Telmisartan and S-Amlodipine(TELMINUVO TAB.) Versus S-Amlodipine Monotherapy in Patients With Stage 2 Hypertension</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chong Kun Dang Pharmaceutical</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chong Kun Dang Pharmaceutical</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of present study is to evaluate the efficacy and safety of two dose combination of
      Telmisartan/S-Amlodipine (80/2.5mg and 80/5mg) compared with S-Amlodipine monotherapy (2.5mg
      and 5mg) in patients with Stage 2 hypertension.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      -  In patients with Stage 2 hypertension to determine the efficacy and safety of
           Telmisartan/S-Amlodipine (80/2.5mg and 80/5mg) or S-Amlodipine monotherapy (2.5mg and
           5mg) during 8 weeks.

        -  This study is consist of placebo run-in period(2 weeks_single blind) and treatment
           period(8 weeks_double blind).
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date>January 2014</start_date>
  <completion_date type="Anticipated">August 2014</completion_date>
  <primary_completion_date type="Anticipated">August 2014</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mean Sitting Systolic Blood Pressure (MSSBP)</measure>
    <time_frame>After 8 weeks of treatment</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mean Sitting Systolic Blood Pressure (MSSBP)</measure>
    <time_frame>After 2 weeks and 4 weeks of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Sitting Diastolic Blood Pressure (MSDBP)</measure>
    <time_frame>After 2weeks, 4weeks and 8 weeks of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Control Rate</measure>
    <time_frame>After 8 weeks of treatment</time_frame>
    <description>Sitting SBP&lt;140mmHg, Sitting DBP&lt;90mmHg</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Response Rate</measure>
    <time_frame>After 8 weeks of treatment</time_frame>
    <description>Reduction of Sitting SBP≥20mmHg, Sitting DBP ≥10mmHg</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Hypertension</condition>
  <arm_group>
    <arm_group_label>TELMINUVO Tab. (80/2.5mg, 80/5mg)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>S-Amlodipine 2.5, 5mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TELMINUVO Tab. (80/2.5mg)</intervention_name>
    <description>Fixed dose combination of Telmisartan 80mg and S-amlodipine 2.5mg QD 2 weeks.
With the others investigation product placebo 1 tab QD 2 weeks.</description>
    <arm_group_label>TELMINUVO Tab. (80/2.5mg, 80/5mg)</arm_group_label>
    <other_name>TELMINUVO Tab.</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TELMINUVO Tab. (80/5mg)</intervention_name>
    <description>Fixed dose combination of Telmisartan 80mg and S-amlodipine 5mg QD 6 weeks.
With the others investigation product placebo 1 tab QD 6 weeks.</description>
    <arm_group_label>TELMINUVO Tab. (80/2.5mg, 80/5mg)</arm_group_label>
    <other_name>TELMINUVO Tab.</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>S-amlodipine 2.5mg</intervention_name>
    <description>S-amlodipine 2.5mg QD 2 weeks
With the others investigation product placebo 1 tab QD 2 weeks.</description>
    <arm_group_label>S-Amlodipine 2.5, 5mg</arm_group_label>
    <other_name>Anydipine S</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>S-amlodipine 5mg</intervention_name>
    <description>S-amlodipine 5mg QD 6weeks
With the others investigation product placebo 1 tab QD 6 weeks.</description>
    <arm_group_label>S-Amlodipine 2.5, 5mg</arm_group_label>
    <other_name>Anydipine S</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  age 18 years or older

          -  at the screening visit

               -  antihypertensive drugs not taking: 160mmHg ≤ sitSBP &lt; 200mmHg

               -  antihypertensive drugs taking: 140mmHg ≤ sitSBP &lt; 180mmHg

          -  at the randomization visit(160mmHg ≤ sitSBP &lt; 200mmHg)

          -  willing and able to provide written informed consent

        Exclusion Criteria:

          -  mean sitting DBP ≥ 120mmHg or mean sitting SBP ≥ 200mmHg at the screening visit and
             randomization visit

          -  for the past four weeks based on beginning of administration, patients took over four
             antihypertensive drugs

          -  known or suspected secondary hypertension(ex. aortic coarctation, Primary
             hyperaldosteronism, renal artery stenosis, pheochromocytoma)

          -  has severe heart disease(Heart failure NYHA functional class 3, 4), ischaemic heart
             diseases status need to treatment, myocardiopathy, Valve disease, arrhythmia and so on
             and operated Coronary angioplasty

          -  has cerebrovascular disease as cerebral infarction, cerebral hemorrhage within 6
             months

          -  Type I Diabetes Mellitus, Type II Diabetes Mellitus with poor glucose control as
             defined by fasting glucosylated hemoglobin(HbA1c) &gt; 8%)

          -  known severe or malignant retinopathy

          -  defined by the following laboratory parameters:

               -  hepatic dysfunction(AST/ALT &gt; UNL X 3)

               -  renal dysfunction(serum creatinine &gt; UNL X 1.5)

               -  hypopotassemia(K &lt; 3.0mmol/L) or hyperpotassemia (K&gt;5.5 mmol/L)

          -  acute or chronic inflammatory status need to treatment

          -  need to additional antihypertensive drugs during the study

          -  need to concomitant medications known to affect blood pressure during the study

          -  history of angioedema related to ACE inhibitors or Angiotensin II Receptor Blockers

          -  known hypersensitivity related to either study drug

          -  history of drug or alcohol dependency within 6 months

          -  any surgical or medical condition which might significantly alter the absorption,
             distribution, metabolism, or excretion of investigational products(ex.
             gastrointestinal tract surgery such as gastrectomy, gastroenterostomy or bypass,
             active inflammatory bowel syndrome within 12 months prior to screening, gastric ulcers
             need to treatment, gastrointestinal/rectal bleeding, impaired pancreatic function such
             as pancreatitis, obstructions of the urinary tract or difficulty in voiding)

          -  administration of other study drugs within 4weeks prior to screening

          -  premenopausal women(last menstruation &gt; 1year) not using adequate contraception,
             pregnant or breast-feeding

          -  history of malignancy including leukemia and lymphoma within the past 5 years

          -  in investigator's judgment
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Ho-Joong Yoon, Ph.D</last_name>
    <phone>82-2-2258-6029</phone>
    <email>younhj@catholic.ac.kr</email>
  </overall_contact>
  <location>
    <facility>
      <name>The catholic university of Korea Seoul St. Mary's hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Ho-Joong Yoon, Ph.D</last_name>
      <phone>82-2-2258-6029</phone>
      <email>younhj@catholic.ac.kr</email>
    </contact>
    <investigator>
      <last_name>Ho-Joong Yoon, Ph.D</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>November 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 7, 2013</study_first_submitted>
  <study_first_submitted_qc>November 7, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 14, 2013</study_first_posted>
  <last_update_submitted>November 7, 2013</last_update_submitted>
  <last_update_submitted_qc>November 7, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 14, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>TELMINUVO Tab.</keyword>
  <keyword>CKD-828</keyword>
  <keyword>Hypertension</keyword>
  <keyword>Stage 2 Hypertension</keyword>
  <keyword>S-Amlodipine</keyword>
  <keyword>Telmisartan</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Telmisartan</mesh_term>
    <mesh_term>Amlodipine</mesh_term>
    <mesh_term>Niacin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

